This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Healthcare's Near-Term Prospects Bright: 3 ETFs in Focus
by Sweta Jaiswal, FRM
The healthcare space might have seen a sluggish year so far. But its valuation and near-term prospects make it a good space for investments right now.
Athenahealth (ATHN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Athenahealth (ATHN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.
Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up
by Zacks Equity Research
Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
by Zacks Equity Research
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
Integra (IART) Rises 5% on Robust Preliminary Q4 Results
by Zacks Equity Research
Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.
Boston Scientific Gains on Impressive Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
ResMed Announces Complete Mobi Launch in US Markets for COPD
by Zacks Equity Research
ResMed (RMD) progresses with efforts to boost Respiratory Care suite.
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
by Zacks Equity Research
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Hologic Stock Rides on Impressive Preliminary Q1 Result
by Zacks Equity Research
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
ResMed Closes Propeller Health Buyout, Boosts COPD Suite
by Zacks Equity Research
ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.
Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.
Neogen's Canadian Lab Buyout to Boost Genomics Business
by Zacks Equity Research
Neogen (NEOG) continues to adopt initiatives to boost the genomics business.
LabCorp Rides on Covance Business Amid Reimbursement Woes
by Zacks Equity Research
Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.
AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife
by Zacks Equity Research
AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
A bullish guidance for 2018 and a series of latest developments make Cerner (CERN) a promising investment pick.
Cerner (CERN) Collaborates With McKesson's CoverMyMeds
by Zacks Equity Research
Cerner's (CERN) ePrescribe workflow solution is likely to partner with CoverMyMeds' RxBenefit Clarity solution for prescription price transparency.
Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?
by Zacks Equity Research
Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
Cerner's (CERN) Millennium Picked by Mid-Valley Hospital
by Zacks Equity Research
Cerner's (CERN) EHR platforms have seen a series of developments in recent times.
4 Medical Device Stocks That More Than Doubled in 2018
by Sweta Jaiswal
Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.
What Bargains? Play 5 Stocks With Rising P/E Instead
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Here's Why You Should Invest in athenahealth (ATHN) Now
by Zacks Equity Research
A strong guidance and focus on big data-based health records system make athenahealth (ATHN) a solid investment pick.
athenahealth (ATHN) Q3 Earnings Beat, Bookings Down Y/Y
by Zacks Equity Research
athenahealth's (ATHN) Business and Services unit sees a strong Q3; 2018 guidance maintained.
100-Year Anniversary of Armistice Day
by Zacks Equity Research
100-Year Anniversary of Armistice Day
Return of Merger Monday: ATHN, SAP & More
by Mark Vickery
Two major buyouts dominate our morning headlines, and both have deep implications for their respective industries.